(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 May 2013 (23.05.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/071355 A1

(51) **International Patent Classification**:
A61K 38/10 (2006.01) *G01N 33/15* (2006.01)
A61K 38/28 (2006.01) *A61P 5/50* (2006.01)
C12N 15/12 (2006.01) *A61P 37/06* (2006.01)
C12N 15/86 (2006.01)

(21) **International Application Number**:
PCT/AU2012/001411

(22) **International Filing Date**:
15 November 2012 (15.11.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/560,254 15 November 2011 (15.11.2011) US
61/705,633 26 September 2012 (26.09.2012) US

(71) **Applicant**: **THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH** [AU/AU]; Wehi, 1G Royal Parade, Parkville, Melbourne, Victoria 3052 (AU).

(72) **Inventors**: **BANDALA SANCHEZ, Esther**; c/- WEHI, 1G Royal Parade, Parkville, Melbourne, Victoria 3052 (AU). **DROMEY, James**; c/- WEHI, 1G Royal Parade, Parkville, Melbourne, Victoria 3052 (AU). **HARRISON, Leonard Charles**; c/- WEHI, 1G Royal Parade, Parkville, Melbourne, Victoria 3052 (AU). **ZHANG, Yuxia**; c/- WEHI, 1G Royal Parade, Parkville, Melbourne, Victoria 3052 (AU). **RASHIDI, Maryam**; c/- WEHI, 1G Royal Parade, Parkville, Melbourne, Victoria 3052 (AU).

(74) **Agent**: **MONGER, Carmela**; WEHI, 1G Royal Parade, Parkville, Melbourne, Victoria 3052 (AU).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2013/071355 A1

(54) **Title**: SOLUBLE MEDIATOR

(57) **Abstract**: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.